| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5587475 | Diabetes Research and Clinical Practice | 2016 | 18 Pages |
Abstract
Pretreatment with OADs is associated with a modest delay in initiating insulin therapy and lower total healthcare costs. The clinical and pharmacoeconomic benefits of pretreatment should be elucidated in a prospective study.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Paresh Chaudhari, Carlos Vallarino, Ernest H. Law, Raafat Seifeldin,